Last reviewed · How we verify
Ascofer (FERROUS ASCORBATE)
Ferrous ascorbate (Ascofer) is a marketed iron supplement with a key composition patent expiring in 2028, competing in a well-established market with other iron salts such as ferrous fumarate, ferrous gluconate, and ferrous sulfate. Its key strength lies in its unique combination of iron and ascorbic acid, which may enhance iron absorption compared to other iron supplements. The primary risk is the strong competition from established generics, which could erode market share and pricing power.
At a glance
| Generic name | FERROUS ASCORBATE |
|---|---|
| Drug class | ferrous ascorbate |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Approved indications
Common side effects
Drug interactions
- dolutegravir
- enoxacin
- levodopa
- levofloxacin
- levothyroxine sodium
- lomefloxacin
- minocycline
- moxifloxacin
- mycophenolate mofetil
- norfloxacin
- ofloxacin
Key clinical trials
- Toddler Biomarker of Nutrition Study (NA)
- The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists (PHASE1)
- Regenerative Potentials of Mature Mandibular Molars With Symptomatic Irreversible Pulpitis Enhanced With Different Scaffolds (NA)
- Urine and Ultrasound Screening for Kidney Disease in Children (NA)
- The Body's Affect on Vitamin C (PHASE1)
- A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC (PHASE2)
- Vitamin C for Acute Kidney Injury in ACLF With Septic Shock: A Randomized Controlled Trial (NA)
- Effects of L-arginine and Liposomial Vitamin C on Severe Copd Patients Undergoing Pulmonary Rehabilitation. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |